Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wave Life SciencesWVE -0.11%61 3-Year Share Buyback Ratio is -29.20 as of Jun. 2026. GuruFocus rates WVE with a GF Score™ of 61/100 and a GF Value™ of $3.82 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,186 Biotechnology companies, Wave Life Sciences ranks worse than 73.19% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Wave Life Sciences's current 3-Year Share Buyback Ratio was -29.20%.
The historical rank and industry rank for Wave Life Sciences's 3-Year Share Buyback Ratio or its related term are showing as below:
WVE'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -36.8 Med: -23.6 Max: -6.3
Current: -29.2
During the past 13 years, Wave Life Sciences's highest 3-Year Share Buyback Ratio was -6.30%. The lowest was -36.80%. And the median was -23.60%.
WVE's 3-Year Share Buyback Ratio is ranked worse than 73.19% of 1186
companies
in the Biotechnology industry
Industry Median: -11.6
vs WVE: -29.20
Wave Life Sciences (NAS:WVE) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Wave Life Sciences 3-Year Share Buyback Ratio Related Terms
WVE vs IMMX, CADL, ARDX: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Wave Life Sciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's 3-Year Share Buyback Ratio falls into.
Wave Life Sciences 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -29.20 mean?
Wave Life Sciences (WVE) has a 3-Year Share Buyback Ratio of -29.20 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Wave Life Sciences and its competitors. According to the industry distribution chart, Wave Life Sciences ranks #868 out of 1186 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Wave Life Sciences' 3-Year Share Buyback Ratio too high?
Wave Life Sciences' current 3-Year Share Buyback Ratio is -29.20. Based on the distribution chart, Wave Life Sciences ranks #868 out of 1186 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Wave Life Sciences has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' 3-Year Share Buyback Ratio compare to IMMX and CADL?
According to the Biotechnology industry distribution chart, Wave Life Sciences ranks #868 out of 1186 companies for 3-Year Share Buyback Ratio. This places Wave Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Wave Life Sciences and its competitors. Wave Life Sciences's current 3-Year Share Buyback Ratio is -29.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $4.58 — trading 19.9% above its estimated fair value. The current 3-Year Share Buyback Ratio is -29.20. Wave Life Sciences' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current 3-Year Share Buyback Ratio is -29.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $4.58 is trading 19.9% above its estimated GF Value™ of $3.82.
GuruFocus considers Wave Life Sciences to be Modestly Overvalued.
Key valuation signals for WVE:
3-Year Share Buyback Ratio: -29.20
GF Value™: $3.82 vs. price of $4.58 (19.9% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
61GF Score
Get the complete analysis for WVE
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
